3
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular Agents (Including Blood Products)

Patent Evaluation: Benzimidazole Class III Antiarrhythmic Agents

Pages 1467-1468 | Published online: 02 Mar 2011
 

Summary

Novelty: Novel propanolamine and propylamine derivatives are claimed to be Class III antiarrhythmic agents.

Biology: An in vivo canine study of antiarrhythmic activity is described. Class III antiarrhythmic activity was defined as an increase in ERP (effective refractory period) without a significant decrease in CT (conduction time). Preferred compounds were found to have an effective dose range of 1–5 mg/kg (iv).

Chemistry: 1-[(1H-Benzimidazol-2-ylmethyl)methylamino]-3-(4-nitrophenoxy)-2-propanol dihydrochloride is one of eleven specifically claimed compounds. Preparative details using standard techniques are presented.

Structure:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.